Royalty Pharma plc (RPRX) Market Cap & Valuation Ratios
Royalty Pharma plc (RPRX) has a market cap of $36.7B, a trailing P/E of 34.0 and a price-to-sales ratio of 14.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RPRXRoyalty Pharma plcFollow RPRX — free
—
Price chart with a free account
- Market cap
- 36.7B
- P/E TTM
- 34.0
- Dividend yield
- 1.1%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RPRX | 37 | 34.0 | 17.7 | 29.6 | 8.1% | +10% | 60% | 10% |
| REGN | 83 | 19.9 | 4.9 | 17.6 | 4.5% | +9% | 25% | 11% |
| MRNA | 80 | — | 33.8 | — | -1.6% | -28% | -149% | -48% |
| RVMD | 40 | — | — | — | -3.1% | — | — | -71% |
| ALNY | 30 | 41.6 | 5.8 | 26.2 | 2.7% | +95% | 21% | 173% |
| ROIV | 26 | — | — | — | -3.1% | -68% | — | -20% |
| INCY | 23 | 14.7 | 3.3 | 10.4 | 8.2% | +27% | 31% | 64% |
| INSM | 20 | — | 17.4 | — | -4.0% | +186% | -74% | -133% |
| EXEL | 16 | 20.3 | 6.2 | 15.2 | 7.3% | +9% | 40% | 47% |
| ASND | 15 | — | — | — | — | +113% | 25% | 11% |
| HALO | 14 | 36.6 | 9.8 | 26.5 | 5.7% | +41% | 36% | 22% |
| Median of these 10 | 20.3 | 6.2 | 17.6 | 2.7% | +27% | 25% | 11% |
P/E 34.0 vs. a peer median of 20.3; EV/Sales 17.7 vs. 6.2. RPRX's own P/E sits at the 71st percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesMRNA and RVMD and ROIV and INSM and ASND have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Royalty Pharma plc — questions
- What is Royalty Pharma plc's market cap?
- $36.7B.
- What is Royalty Pharma plc's P/E ratio?
- 34.0 on trailing twelve-month earnings to 2026-06-30.
- What is Royalty Pharma plc's price-to-sales ratio?
- 14.5.
Every figure on this page comes from Royalty Pharma plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.